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Abstract
Background: Org 25435 is a new water-soluble alpha-amino acid ester intravenous anaesthetic which proved
satisfactory in animal studies. This study aimed to assess the safety, tolerability and efficacy of Org 25435 and to
obtain preliminary pharmacodynamic and pharmacokinetic data.
Methods: In the Short Infusion study 8 healthy male volunteers received a 1 minute infusion of 0.25, 0.5, 1.0, or 2.0
mg/kg (n = 2 per group); a further 10 received 3.0 mg/kg (n = 5) or 4.0 mg/kg (n = 5). Following preliminary
pharmacokinetic modelling 7 subjects received a titrated 30 minute Target Controlled Infusion (TCI), total dose 5.8-
20 mg/kg.
Results: Within the Short Infusion study, all subjects were successfully anaesthetised at 3 and 4 mg/kg. Within the
TCI study 5 subjects were anaesthetised and 2 showed signs of sedation. Org 25435 caused hypotension and
tachycardia at doses over 2 mg/kg. Recovery from anaesthesia after a 30 min administration of Org 25435 was
slow (13.7 min). Pharmacokinetic modelling suggests that the context sensitive half-time of Org 25435 is slightly
shorter than that of propofol in infusions up to 20 minutes but progressively longer thereafter.
Conclusions: Org 25435 is an effective intravenous anaesthetic in man at doses of 3 and 4 mg/kg given over 1
minute. Longer infusions can maintain anaesthesia but recovery is slow. Hypotension and tachycardia during
anaesthesia and slow recovery of consciousness after cessation of drug administration suggest this compound has
no advantages over currently available intravenous anaesthetics.
Background
The GABA-a receptor mediates the effect of structurally
diverse anaesthetics [1] and is a key target for intrave-
nous hypnotics including etomidate, thiopentone,
alphaxalone and propofol [2,3]. Current intravenous
anaesthetics, such as propofol, are sparingly soluble in
water and are therefore presented in complex formula-
tions which may present problems including anaphylaxis
and lipid accumulation. A water-soluble anaesthetic,
minaxolone was developed in an attempt to avoid com-
plex formulation issues but was ultimately withdrawn
due to an unacceptable level of muscle movement and
concerns over carcinogenicity.
In an attempt to develop a water-soluble alternative to
propofol, a series of alpha-amino acid esters were
synthesised from which Org 25435 ([2,6-dimethoxy-4-
methylphenyl-2’-N-bis(2’-methoxyethyl) aminobutyrate
HBr], Figure 1) was selected for clinical studies. Exten-
sive pre-clinical evaluation showed it to be a potent
intravenous anaesthetic with sleep times in mice com-
parable to propofol and a therapeutic index of 12 [4].
Org 25435 is an allosteric modulator of the GABA-a
receptor and inhibited binding of [35S]t-butylbicyclo-
phosphorothionate to the GABA-a receptor channel
complex and potentiated the effects of GABA in oocytes
expressing a1b3g2 containing receptors with a potency
comparable to that of propofol in the same assay [4].
Additional animal studies were performed in mice,
rats, dogs, and marmoset monkeys [4,5]. In these stu-
dies, Org 25435 was shown to induce and maintain
anaesthesia with rapid offset when drug administration
was discontinued [6]. Org 25435 exhibited an acceptable
behavioural and cardiovascular profile, such that admin-
istration of Org 25435 to healthy human volunteers
could be justified. Based on the data from the animal
studies the anticipated human dose was approximately 1
to 4 mg/kg. The objectives of this study were to assess
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intravenous anaesthetic in healthy young male volun-
teers following a single intravenous infusion of 1-30
minutes and to determine preliminary pharmacody-
namic and pharmacokinetic characteristics of the
compound.
Methods
The protocol and subsequent amendments were
reviewed and approved by the Independent Ethics Com-
mittee (Plymouth) (Non-NHS Phase 1). All subjects
gave written consent to participation. Clinical Trial
Exemption Certificate, CTX, was not required for this
study. The clinical trials registration number is
NCT01062867.
Setting and study subjects
The study was conducted in a specialist clinical trials unit
with standard equipment for induction and maintenance
of anaesthesia and subsequent supervised recovery. We
studied healthy male subjects who were non-smokers and
consumed less than 20 units of alcohol (< 160 g) per
week. All subjects underwent standard medical screening
including laboratory investigations within 3 weeks of
scheduled dosing.
Study drug
Org 25435 was supplied as a freeze-dried cake stored at
2-8°C and reconstituted with water to 20 mg/ml.
Short Infusion study
This was a dose escalation study. Dosing began at 0.25
mg/kg infused over one minute and increased to 0.5,
1.0, 2.0, 3.0, 4.0, 5.0 and 6.0 mg/kg in subsequent sub-
jects. Beginning with the lowest dose, two subjects
were studied at each dose. Once general anaesthesia
occurred in any volunteer, the number of subjects stu-
died at that dose and upwards increased to five. The
study proceeded to one dose level above the first level
at which three or more of the five subjects experienced
general anaesthesia. Anaesthesia was defined as loss of
speech contact, loss of eyelash reflex and dropping of a
water-filled syringe. Where there was ambiguity or
doubt, the decision as to whether or not anaesthesia
occurred was taken by the senior anaesthetist present.
Video recordings were available for review if necessary.
Recovery endpoints included time of eye-opening on
command and time of limb movement on command.
Target Controlled Infusion (TCI)
A TCI study was performed after completion of the
S h o r tI n f u s i o ns t u d ya n da ppropriate evaluations of
safety. An interim evaluation of the pharmacokinetic
data of the subjects treated in the Short Infusion study
was performed to provide the pharmacokinetic para-
meter estimates which were used to control the infusion
rate of the pump during the TCI. The TCI was given by
a Harvard 22 pump controlled by STANPUMP software
running on a personal computer. The 30 minute TCI
aimed to achieve stable arterial plasma concentrations
providing for a stable period of anaesthesia. Stable
anaesthesia was defined as anaesthesia lasting for a con-
secutive period of 10 minutes or more.
TCI infusion scheme
The 30 minute TCI was divided into two sections: 0-15
minutes and 15-30 minutes.
First TCI subject
The initial target concentration was based on the mean
Org 25435 concentration occurring at the time at which
eyes were opened on command in the short infusion
study and evaluated using simulation to ensure that the
total dose received (including any upwards titration), did
not exceed 1.5 times the maximum dose given in the
Short Infusion study.
If anaesthesia was achieved and maintained during the
0-15 minute section, the target concentration was to be
maintained for the 15-30 min section; otherwise, after
the first 0-15 minute section, the target concentration
was to be increased by 50% for the remaining 15-30
min section.
Subsequent TCI subjects
The target concentration for the 0-15 minute infusion
interval was to be set to the target concentration of the
previous volunteer during the 15-30 minute infusion
i n t e r v a l .H o w e v e r ,i fa n a e s t h e s i aw a salways observed
from the first volunteer onwards during the 0-15 minute
infusion interval, the TCI target concentration during
the 0-15 minute infusion interval for the next volunteer
was to be set to 2/3 times the TCI target concentration
of the previous volunteer during the 15-30 minute infu-
sion interval.
Once stable anaesthesia was identified using the above
rules in two volunteers at the same target concentration
over the complete period of 30 minutes, the remaining
volunteers to a maximum of seven were to be studied at
Figure 1 Structure of Org 25435 [2,6-dimethoxy-4-
methylphenyl-2’-N-bis(2’-methoxyethyl) aminobutyrate HBr].
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which previous volunteers were studied. Dose escalation
proceeded only after evaluation of safety and efficacy
including review of all clinical and laboratory data (hae-
matology and biochemistry) the response of subjects to
dosing and comments from attending investigators.
The performance of the TCI model was assessed ret-
rospectively by calculation of the bias, accuracy, diver-
gence and wobble [7].
Pre-study preparations
Hartmann’s Solution was infused intravenously
(3 ml kg
-1 hr
-1)f r o ma tl e a s t3h o u r sp r i o rt ot h e
anticipated time of drug administration to ensure ade-
quate hydration whilst fasting. An arterial cannula was
inserted and a second venous cannula placed in an
ante-cubital vein for infusion of Org 25435. Arterial
blood samples (5 mL) were collected at 0, 1, 1.5, 2, 3,
4, 5, 8, 12, 16, 20, 45, 60, 120, 180, and 240 minutes
after the start of infusion in the short infusion study
and at 0, 3, 7, 11, 15, 18, 22, 26, 30, 30.5, 31, 32, 34,
37, 41, 45, 49, 59, 74, 89, 149, 209, and 269 minutes in
the TCI study. The sample at 15 minutes was taken
just prior to the potential alteration in target concen-
tration. The sample at 30 minutes was taken just prior
to stopping the infusion. A sample was also collected
at the time eyes were opened to command.
Venous blood samples (5 mL) were collected at 60,
120, 180, 240, 360, and 720 minutes in the short infu-
sion study and at 389, 509, and 749 minutes in the TCI
study. Blood samples were processed to serum and
stored at 20°C until analysis.
Urine was collected for 24 hours from subjects partici-
pating in the 4 mg/kg dose group of the Short Infusion
study and in the TCI study.
After a stabilization period, during which baseline
measurements were obtained, the anaesthetic infusion
was started without notice. The times of eye closure,
dropping water filled syringe, loss of eyelash reflex, eye
opening on command and limb movement on command
were recorded.
For safety reasons adverse events were recorded
throughout the study.
Electroencephalogram
Frontal electroencephalogram (differential recordings
between FP1, FP2 locations international 10/20 system)
was recorded from all volunteers using custom built
equipment. Absolute power in two frequency bands,
delta power (0.5-3.0 Hz) and theta power (3.25-8.0 Hz)
were continuously calculated in subsequent epochs of 4 s.
Quantification of Org 25435
Org 25435 and its internal standard, Org 24446, were
isolated from serum using solid-phase extraction. Briefly,
10 ng Org 24446 was added to each 0.5 mL serum sam-
ple and the sample was vortex mixed for 3 seconds. The
solid phase extraction cartridge (C18 (end-capped), 50
mg, 1 mL (ICT)) was conditioned with 1 mL methanol,
followed by 1 mL water and then the serum sample was
applied to the cartridge and allowed to run through
under vacuum. The cartridge was then washed twice
with 1 mL water. Org 25435 and Org 24446 were eluted
from the cartridge with 1 mL acetonitrile.
The extracted samples were quantified by liquid chro-
matography (LiChroCART® 55-2 Purospher® STAR RP-
18 endcapped (3 μm)), coupled to a mass spectrometer
(API 3000, Applied Biosystems) using turbo ion spray in
multi reaction monitoring (MRM) mode, operating at
350°C and 5000 V. The mobile phase was run isocrati-
cally at a flow rate of 250 μL/min and consisted of 80%
acetonitrile, 20% 0.01 mol/L ammonium acetate solu-
tion, pH = 4.2. The column oven temperature was set to
40°C. Operating conditions for the API 3000 were as
follows: nebuliser gas 13, collision gas 5, turbo heater
gas 8 L/min. The protonated M + H
+ peak of Org
25435 (m/z 369.9) was used as the precursor ion and in
the MRM-mode m/z 174.2 was measured as the product
ion. The protonated M+H
+ peak of Org 24446 (m/z
355.9) was used as the precursor ion and in the MRM-
mode m/z 174.2 was measured as the product ion.
The lower limits of quantification of the assays were
5 ng/mL (serum) and 1 ng/mL (urine). The plasma assay
was linear across the range 5 to 2000 ng/mL (r = 0.992).
The plasma intra-assay coefficient of variation (CV) was
less than 13% across the calibrated range, while the inter-
assay CV was less than 15%. The urine assay was linear
across the range 1 to 500 ng/mL (r = 0.997). The urine
intra-assay coefficient of variation (CV) was less than 6%
across the calibrated range, while the inter-assay CV was
less than 12%.
Pharmacokinetic modelling and simulation
Moment analysis was performed using standard techni-
ques. Mixed-effects population models [8] were fitted to
the Org25435 plasma concentration versus time data
using the first order estimation method of the program
NONMEM [9]. Arterial plasma concentrations were
used preferentially (over venous concentrations) where
available. When not available e.g. time points post 240
minutes (post 269 minutes in the TCI studies) after
administration of the study drug, venous concentrations
were used for analysis. Three-compartment kinetics
were assumed for the interim model whereas three- and
four-compartment models were compared for the final
model. Models were parameterized in clearances and
volumes. Parameters describing inter- individual varia-
bility (etas) were tested for their significance one at a
time and were retained in the final population model if
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follows: Pi = PTV*exp(etai)w h e r eP i is the parameter
value in the ith subject, PTV is the typical value of the
parameter in the population, and etai is a random vari-
able with a mean of 0 and a variance of omega
2.V a r -
ious residual errors models (proportional, additive and
combined) were explored.
Two population models were produced:
1) An interim model describing Org25435 kinetics
following short infusion. This was subsequently used
for computer-controlled drug administration in the
TCI study. The structural parameters (volume and
clearances) for this model were assumed to vary
according to volunteer body weight.
2) A final population model derived from Org25435
plasma concentration versus time data from both
the short infusion and TCI studies. For the final
population analysis which combined data from the
short infusion study and the TCI study, the potential
relationships between body weight and individual
parameter estimates were explored.
The statistical significance of each proposed covariate-
parameter relationship and the requirement for ETA
parameters was assessed using the likelihood ratio test
(where appropriate i.e. for nested models) and by con-
sideration of the Akaike Information Criterion (non-
nested models) and the precision of the final parameter
estimates (all models). For nested models, the justifica-
tion for each additional effect was for it to improve the
goodness-of-fit statistic (-2 log likelihood) by more than
6.6 (evaluated against the chi-square distribution, this is
equivalent to significance at the 0.01 level). The
improvement (or lack of) in model goodness-of-fit was
also assessed visually by the examination of diagnostic
plots. After completing the model build, the necessity
for each added component was re-assessed by removing
it from the model and evaluating the resulting impact
on the model fit. If the removed component caused an
increase in the goodness-of-fit statistic equivalent to sig-
nificance at the 0.005 level (i.e. the removal of the com-
ponent significantly worsened the model), it was allowed
to remain.
Pharmacodynamic modelling
A sequential approach was taken to pharmacokinetic-
pharmacodynamic modelling. That is, the final population
pharmacokinetic model was used to derive individualised
(post-hoc Bayesian) pharmacokinetic parameter estimates
(e.g. rate constants and central compartment volume)
for each volunteer in the short infusion groups. These
were used as inputs, along with the drug dose and effect
measure data, for the estimation of pharmacodynamic
parameters. The absolute power in the theta band (3.25-
8.0 Hz) was used as an effect measure and was described
using a sigmoid Emax model of Org 25435 concentration
(CE) in an effect site compartment, according to the fol-
lowing equation:
Effect E E E CE EC CE =+ − () + 00 5 0 max *( )/( )

where E0 is the baseline value, Emax is the maximum
response, EC 50 is the effect site concentration corre-
sponding to half of the maximum effect, and g (Hill
coefficient) describes the steepness of the drug concen-
tration-effect relationship. The incorporation of a
hypothetical effect compartment accounted for the hys-
teresis (temporal delay) between serum Org 25435 con-
centration and the onset of drug effect. This delay was
characterised by the estimation of Ke0, the blood-brain
equilibration rate constant. NONMEM’s first order con-
ditional estimation method was used. Random residual
error was described using an additive model. A propor-
tional variance model was used to describe the inter-
individual variability in Emax,E C 50 and Ke0 and E0.
Results
Nineteen healthy male volunteers were included into the
dose escalation study and an additional 7 volunteers
participated in the TCI study. Volunteers were 27.7 ±
4.8 years, weight 75.2 ± 7.6 kg, Body Mass Index 23.6 ±
2.1 kg/m2. Data are means ± SD. Two subjects per
group received Org 25435 at 0.25, 0.5, 1.0, or 2.0 mg/kg;
5r e c e i v e d3 . 0m g / k ga n d5r e c e i v e d4 . 0m g / k gi nt h e
short infusion study. Subject 10 (scheduled to receive 3
mg/kg) was excluded as the infusion was immediately
terminated due to a leak. This subject was not included
in any analysis except for safety.
Induction and maintenance of anaesthesia
During the Short Infusion study, at 2 mg/kg both sub-
jects were unresponsive but did not drop the syringe.
All subjects were successfully anaesthetised at doses of
3.0 and 4.0 mg/kg.
Based on the mean Org 25435 concentration occur-
ring at the time at which eyes were opened on com-
mand, a concentration of 5000 ng/mL was chosen as
the target concentration for the first subject in the TCI
study. Taking into account that the TCI target concen-
tration during the 15-30 minute infusion interval was to
be increased by 50% if stable anaesthesia was not
observed in the 0-15 minute infusion interval, i.e. 7500
ng/mL, the maximum total amount infused in the first
subject would be less than 6 mg/kg. Following interim
pharmacokinetic modelling, 7 subjects received a titrated
30 minute Target Controlled Infusion (TCI). Total doses
administered were: 5.8, 8.9, 12.9, 12.7, 14.8, 20.0 and
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plasma concentrations for each subject during the 30
minute infusion. Within the TCI study two subjects
were observed to show periods of sedation, which ligh-
tened towards the end of the infusion, the other five
subjects were successfully anaesthetised. Six out of 7
TCI subjects showed some evidence of twitching or
other involuntary movements. The 5 anaesthetised sub-
jects opened their eyes on command at 13.7 minutes
and moved their limbs on command at 16 minutes after
the TCI had finished, data are means.
The median absolute performance error (MDAPE) of
the TCI pharmacokinetic model was 35.5%, the median
performance error (MDPE) was -35.5%. The median
values for divergence and wobble were 0.66%/hour and
10.8% respectively.
Org 25435 serum concentration at ‘time eyes opened on
command’
For subjects 9-19 belonging to dose groups 3 and 4 mg/kg
an arterial blood sample was taken at the time at which
the eyes were opened on command. The mean Org 25435
concentration at which eyes were opened on command
was 4462 ng/mL (median 4679 ng/mL). Table 1 provides
the times of occurrence of various markers of sedation
and the associated predicted effect site concentration of
Org25435 for subjects in the short infusion group.
Haemodynamics
Short infusions of Org 25435 at anaesthetic doses
caused an immediate reduction in arterial blood pres-
sure with an increase in heart rate. During TCI, there
was a sustained reduction in arterial pressure and
increase in heart rate and which gradually resolved after
the infusions were discontinued. Systolic arterial pres-
sure fell from 146 ± 13 to a minimum of 113 ± 14
mmHg at 37 min. The heart rate of subjects receiving
TCI increased from 70 ± 6 beats min
-1 to a maximum
of 102 ± 14 at 9 min. See Figure 3.
Safety
There were 20 adverse events reported during the study
including 6 reports of headaches and 2 cases of hot flushes.
None of the adverse events were considered serious.
Electroencephalogram
All electroencephalogram traces were inspected visually;
no spiking or epileptiform activity was seen. Power
Figure 2 Target and measured Org25435 plasma concentrations for each volunteer during the two 15 minute stages of the 30 minute
infusion. NB For volunteers 4 and 5, the target concentration remained the same (16.9ï¿½g/mL) for the entire 30 minute period.
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ing before 2 minutes after the start of injection in most
volunteers. Between 2 and 10 minutes, the effects
washed out gradually. At the higher doses (3 and 4 mg/
kg), after return of verbal contact, delta and theta power
was still slightly higher than baseline, possibly indicating
a residual light sedation.
Pharmacokinetic analysis
Pharmacokinetic modelling was based on arterial plasma
concentrations for the first four hours post-dose. Venous
plasma concentrations were used for later time points i.e.
360 minutes onwards. The relative concentration differ-
ence, calculated as ((venous concentration-arterial con-
centration)/arterial concentration) in the 240 minute
post-dose sample (latest sample for which both sample
matrices were available) was always less than 1 ng/mL.
1) Short Infusion Study
Measured concentrations of Org 25435 from all sub-
jects in the Short Infusion study are shown in Figure 4.
Pharmacokinetic parameter estimates for the interim
model, based on the Short Infusion study data only, are
provided in Table 2.
2) Short Infusion & TCI Studies
Moment Analysis
Individual pharmacokinetic parameters calculated with-
out assuming a specific compartment model are pre-
sented as Additional File 1. Plots of area-under-the-
curve versus Org 25435 dose, for both short infusions
Table 1 Infusion study: induction of anaesthesia and recovery times
Median Min Max Mean effect site conc
n [SD] n
2m gk g
-1 (n = 2) Time in minutes μgm L
-1
Cessation of speech 0.9 0.8 0.9 6.2 2
Eye closure 0.9 0.8 0.9 6.2 2
Syringe drop 0
Loss of eyelash reflex 1.7 1.7 1.7 10.9 1
Eyes open on command 2.1 2 2.2 8.3 2
Limb movement on command 2.1 2 2.2 8.3 2
3m gk g
-1 (n = 5)
Cessation of speech 0.8 0.5 0.9 8.3 [2.5] 5
Eye closure 0.8 0.8 1.1 10.3 [1.6] 5
Syringe drop 0.9 0.8 1.3 10.5 [1.5] 3
Loss of eyelash reflex 1.1 0.9 1.3 11.8 [2.1] 5
Eyes open on command 3.3 3.3 5.3 5.9 [1.3] 5
Limb movement on command 4.1 3.3 6.4 5.4 [1.4] 5
4m gk g
-1 (n = 5)
Cessation of speech 0.7 0.5 0.8 8.0 [1.4] 5
Eye closure 0.7 0.7 0.8 9.5 [0.7] 5
Syringe drop 0.9 0.7 1.2 12.2 [2.0] 5
Loss of eyelash reflex 1.2 1 2 15.5 [2.6] 5
Eyes open on command 5.3 3.2 9.2 6.4 [1.1] 5
Limb movement on command 5.8 3.7 9.4 6.1 [0.9] 5
Mean effect site concentration is the averaged individualised model predicted value of Org25435 in the biophase at time for each event.
Figure 3 Mean arterial blood pressures and heart rate before
and after administration of 4 mg/kg Org 25435 over 1 minute,
n = 5. The injection of Org 25435 caused an immediate
tachycardia.
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non-linear pharmacokinetics (data not presented).
Urinary Excretion
0.005 ± 0.003% and 0.013 ± 0.001%, mean ± SD respec-
tively of the administered dose was excreted unchanged
between 0 and 24 hours.
Population modelling
Pharmacokinetics As a first step three- and four-com-
partment mamillary models were compared. The four-
compartment model described the data significantly
better than the three-compartment model. The influence
of body weight on the pharmacokinetic parameter esti-
mates was then systematically examined. A four-compart-
ment model, in which the structural parameters (volumes
and clearances) increased in proportion to the individual’s
body weight, performed better than a model in which CL
was not weight-normalised. Final model pharmacokinetic
parameter estimates are shown in Table 3. Goodness-of-
fit plots for this model are shown as Figure 5.
Pharmacodynamic modelling
Pharmacodynamic modelling was performed using the
electroencephalogram data (absolute power in theta
band) from the fourteen volunteers in the short infusion
group (dose range 1 to 4 mg kg
-1). Parameter values and
plots of observed and model predicted values for theta
for the volunteers who received 4 mg kg
-1,a r eg i v e ni n
Table 4 and Figure 6, respectively.
Discussion
The purpose of this study was to determine whether
Org 25435 could induce anaesthesia in man and to eval-
uate safety in a limited number of subjects. The target
controlled infusion (TCI) phase of the study explored
the suitability of Org 25435 for maintenance of
anaesthesia.
Figure 4 Arterial concentrations of Org 25435 in 18 subjects receiving 0.25-4 mg/kg. The measured concentrations have been normalized
to a dose of 1 mg/kg.
Table 2 Pharmacokinetic parameter values for the
interim model
Parameter Typical Value (SE)
CL mL kg
1 min
1 7.99 (0.0241)
Q2 mL kg
1 min
1 68.7 (2.97)
Q3 mL kg
1min
1 9.33 (0.506)
V1 mL/kg 57.7 (3.46)
V2 mL/kg 335 (9.90)
V3 mL/kg 993 (26.8)
Data are typical values (standard error). CL = irreversible systemic clearance
from the central compartment; Q2 = distribution clearance for the rapidly
equilibrating peripheral compartment; Q3 = distribution clearance for the
slowly equilibrating peripheral compartment; V1= volume of the central
compartment; V2 = volume of the rapid peripheral compartment;
V3 = volume of the slow peripheral compartment.
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All subjects receiving the short (1 minute) infusions
of 3 mg/kg or more became anaesthetised. This
induction dose was within the predicted range from
animal data.
The characteristics of the induction of anaesthesia
were satisfactory. We were not able to definitively evalu-
ate pain on injection because the drug was infused
through an ante cubital vein. The sequence of induction
“end points” also fitted with similar data from estab-
lished intravenous agents. Specifically, the sequence was
consistently loss of speech, then eye closure, then syr-
inge drop, followed by loss of lash reflex.
For the minority of subjects (the 2 mg/kg group) who
experienced sedation with a sub-anaesthetic dose of Org
25435, the experience was satisfactory. In those subjects
who became anaesthetised (doses of 3 mg/kg and 4 mg/
kg, n = 10) there was unequivocal anaesthesia which
was clinically similar to that achieved with other agents.
The small excitatory movements observed in 4 of the 10
subjects receiving 3 or 4 mg/kg did not compromise the
safety of the subjects.
Table 3 Org 25435 pharmacokinetic parameter estimates.
The model is based on 18 short (1 minute) infusions and
7 Target Controlled Infusions (30 minutes)
Parameter Typical Value 95% Confidence Interval CV%
CL mL kg
-1 min
-1 8.31 7.23-9.39 31.3
Q2 mL kg
-1 min
-1 13.7 -18.2* -45.6
Q3 mL kg
-1 min
-1 62.8 30.3-95.3 61.4
Q4 mL kg
-1 min
-1 12.4 7.47-17.3 35.4
V1 mL kg
-1 min
-1 38.7 18.9 - 58.5
V2 mL kg
-1 min
-1 56.2 -65.8* - 178
V3 mL kg
-1 min
-1 642 393 - 891 68.5
V4 mL kg
-1 min
-1 1380 1137 - 1624 8.5
Residual variability % 20.3 13.9 - 25.1
Confidence intervals were calculated as the typical parameter estimate ± 1.96
x standard error of the estimate. The coefficient of variation (CV%) was
calculated as the square root of the variance of the eta variable associated
with that parameter. CL = irreversible systemic clearance from the central
compartment; Q2 = distribution clearance for the rapidly equilibrating
peripheral compartment; Q3 = distribution clearance for the slower
equilibrating peripheral compartment; Q4 = distribution clearance for the
slowest equilibrating peripheral compartment; V1= volume of the central
compartment; V2 = volume of the rapid peripheral compartment; V3 =
volume of the slower peripheral compartment; V4 = volume of the slowest
peripheral compartment. * These confidence intervals are symmetric
approximations, the true confidence interval does not contain zero.
Figure 5 Plots demonstrating the performance of the final pharmacokinetic model. Panels A and B show the observed ORG25435 plasma
concentration versus the population model predicted and individualized model predictions, respectively, demonstrating the overall model
goodness-of-fit. Panel C shows the absolute values of the weighted residuals (approximating to standard deviation units) for the individualized
model (IWRES) versus the individualized predictions. Panel D shows the weighted residuals (WRES) versus time.
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Page 8 of 11The increase in heart rate, and decrease in blood pres-
sure, was consistent and substantial. Although our
volunteers were healthy young males, similar changes
induced in patients with cardiovascular instability or
compromised myocardium would be a real clinical pro-
blem. Volunteer studies of a new intravenous formula-
tion are potentially stressful for unpremedicated anxious
subjects and it is possible that sympathetic activity was
increased by factors unrelated to the study drug.
The electroencephalogram effects of Org 25435 are
similar to those of other anaesthetics (synchronization
of the electroencephalogram, shift in power towards
lower frequencies) Time to maximum electroencephalo-
gram effect after a Short Infusion was fast (mean pre-
dicted time to peak effect 1.42 minutes (SD 0.12), Ke0
half life was 0.86 min, 95% CI 0.80 - 0.93) and the bulk
of the EEG effects vanished within 4 to 8 minutes.
Target controlled infusions
The TCI treatments induced anaesthesia in five subjects,
the remaining two showing periods of sedation. The
sedation/anaesthesia status of the subjects was not con-
sistent during each of the plateaux and tended to lighten
with the passage of time. This was confirmed by the
measured arterial blood concentrations which tended to
fall with time, presumably due to the inability of the
preliminary pharmacokinetic model to adequately
describe drug disposition during longer infusions. The
modest excitatory phenomena seen during the short
infusions, and subsequent anaesthesia appeared more
often and to a greater magnitude in the subjects in
whom anaesthesia was maintained. Not all the excitatory
phenomena were comparable to those routinely seen
with propofol [10]. Specifically some were greater
including whole arm movements. The interpretation of
these is somewhat complicated because the drug con-
centration was (in retrospect) known to be changing.
The positive value derived for model divergence (0.66%/
hour) indicates that the difference between predicted
and actual Org25435 plasma concentrations increased
over time. It is possible that the depth of anaesthesia
progressively lightened and may have rendered the sub-
jects into a condition more likely to develop excitation.
Recovery from TCI was slow. The relatively fast recov-
ery from bolus/short infusions suggests that rapid distri-
bution into peripheral compartments terminates the
drug effect. However, the equilibration between com-
partments which takes place during a longer infusion
exposes the importance of drug elimination. The value
Table 4 Pharmacodynamic parameters
Parameter Typical Value 95% Confidence Interval CV%
E0 0.158 -0.02 - 0.336 114
Emax 17.8 15.6 - 19.9 93.3
EC50 ng/mL 7580 6699 - 8461 22.2
Gamma 6.28 5.03 - 7.53 35.6
Ke0(min
-1) 0.808 0.746 - 0.870 12.6
Ke0 half life (min) 0.858 0.797 - 0.929
Residual error 1.98 1.55 - 2.34
Confidence intervals were calculated as the typical parameter (geometric
mean) estimate ± 1.96 x standard error of the estimate. The coefficient of
variation (CV%) was calculated, where possible, as the square root of the
variance of the eta variable associated with that parameter.
Figure 6 Observed (marker), population model predicted (dashed line) and individualised model predicted (solid line) values of
absolute theta power in the volunteers receiving Org 25435 at 4 mg kg
-1.
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Page 9 of 11for metabolic clearance of Org25435 derived in this
study, at 8.2 mL/kg/min, was approximately half the
predicted value obtained from allometric scaling of pre-
clinical pharmacokinetic data in rats and may partially
explain the slower than anticipated recovery observed in
this study after 30 minute infusions. It is well known
that animals are imperfect predictors of drug handling
in humans. Drugs may be metabolised in animals via
pathways that are minor or absent in humans, leading
to a slower than expected clearance. Certainly, there
appears to be a meaningful clinical “problem” with
recovery from longer infusions of Org25435 which was
not anticipated from the preclinical studies [4]. Failure
to predict slow recovery from 30 min infusions in man
may reflect the limitations of extrapolating from brief
infusions in small animal species. Successful extrapola-
tion from rats to humans has been made for thiopental
but the underpinning modelling was based on extensive
prior knowledge of tissue kinetics [11].
Pharmacokinetics
A negligible percentage of the Org 25435 dose adminis-
tered was excreted in the urine unchanged, indicating
that metabolism is the major mechanism for elimination
of the compound. Currently, little is known about the
metabolic products of Org25435 in man.
The moment (non-compartmental) and population
pharmacokinetic analysis revealed no evidence of non-
linear pharmacokinetics. However, the interim pharma-
cokinetic model developed from the short bolus infusion
data failed to adequately predict the Org 25435 concen-
trations during controlled infusion. Fits of the final
pharmacokinetic model developed using the concentra-
tion data from both the short bolus infusions as well as
TCI, show that the final model does predict a fall in
concentrations during TCI. In retrospect, moving to 30
minute TCI using a model derived from 1 min infusions
was over-ambitious and the resulting non-stable anaes-
thesia was experimentally unsatisfactory. Future studies
might usefully start with 10 min zero-order infusions to
clearly define the hysteresis between arterial concentra-
tions and brain effect and then move to shorter infu-
sions to replicate clinical practise at induction and
longer fixed rate infusions before attempting TCI.
The context-sensitive half-time has been proposed as
a useful descriptor of post-infusion central compartment
kinetics, and in connection with that, of recovery from
drug effect [12,13]. Using a preliminary 3-compartment
pharmacokinetic model based on the TCI data only,
context-sensitive half-times of Org 25435 were predicted
for infusions of varying duration. The context-sensitive
half-time, although initially short (2 minutes) after a 10-
minute infusion, increases progressively with increasing
duration of infusion, reaching a value of 50 minutes
after a 90 minute infusion. For comparison the pre-
dicted value for propofol was approximately 7 minutes
[14], see Figure 7. Based on the concept of context sen-
sitive half time, times to recovery from anaesthesia are
expected to increase with increasing duration of Org
25435 infusion. This fits in with the prolonged time to
recovery observed after 30 minute TCI compared to the
short bolus infusions. However, extrapolation beyond 30
minutes is to go beyond the underpinning data and is,
therefore speculative.
Pharmacodynamic
We elected to collect raw EEG rather than use a simplified
derived index of anaesthetic depth. This approach allowed
us to look carefully for excitatory cortical phenomena
whilst also providing a continuous measure of drug effect.
Our modelling demonstrates that Org 25435 enjoys rela-
tively rapid access to the effect site, with an estimated KeO
half-life of 0.9 minutes. This contributes to the prompt
return of consciousness after bolus injections but is out-
weighed by tissue accumulation which accounts for the
slow recovery following extended infusion.
It was crucial for the correct characterisation of pharma-
codynamics that our initial blood samples were arterial. In
their studies of thiopental disposition, Homer and Stanski
were only able to characterise KeO in patients from whom
arterial, rather than venous, samples were collected [15].
Ideally, arterial samples would be collected for the entire
duration of a pharmacokinetic study; however this is rarely
achievable in clinical practice. Our approach of continuing
to collect venous samples when arterial samples were no
longer available, and thus accepting small arterio-venous
differences beyond four hours, allowed full characterisa-
tion of the compound’s elimination half-life and volume of
distribution. To have ceased sampling at the time of arter-
ial line removal would likely have greatly biased our data
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Figure 7 Context sensitive half-time profiles for propofol and
Org 25435 (kinetics based on TCI data only). Context sensitive
half-time is defined as the time required for the plasma drug
concentration to decline by 50% after termination of a drug
infusion. The ‘context’ refers to the infusion duration.
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Page 10 of 11as the estimation of pharmacokinetic parameters is known
to correlate with duration of sampling time [16]. For our
data, at 240 minutes the arterial sample concentration was
only 12.2 +/- 10.5% lower than the venous concentration
and this difference would likely have been even smaller at
360 minutes, the time at which the first venous data
entered the pharmacokinetic modelling process.
Conclusions
Org 25435 is an effective intravenous anaesthetic in man
at doses of 3 and 4 mg/kg, when administered over 1
minute. The adverse event profile of Org 25435 is unre-
markable. No safety problems were seen with this pre-
paration except for some cardiovascular phenomena and
mild involuntary movements. Longer infusions can
maintain anaesthesia but subsequent recovery is slow.
Hypotension tachycardia during anaesthesia and slow
recovery of consciousness after cessation of drug admin-
istration suggest this compound has no advantages over
currently available intravenous anaesthetics.
Additional material
Additional file 1: Results of moment analysis. This file contains a
summary table of non-compartmental pharmacokinetic parameter values
(Means (SD)).
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